Jennifer Kaufman-Shaw
Corporate Officer/Principal bei Zymeworks BC, Inc.
Profil
Jennifer Kaufman-Shaw was the founder of ImStar Therapeutics, Inc. (founded in 2012) where she held the title of VP-Intellectual Property & Legal Affairs from 2012 to 2014.
She is currently working as Vice President-Intellectual Property at Zymeworks BC, Inc. since 2014.
Additionally, she is a Member of the Alberta Bar Association and the British Columbia Bar Association.
In her former positions, she worked as a Director at MRM Proteomics, Inc., Vice President-Patent Counsel at QLT, Inc. from 1997 to 2007, and Vice President at Sirius Genomics, Inc. from 2007 to 2012.
Dr. Kaufman-Shaw obtained her graduate and doctorate degrees from the University of Alberta.
Aktive Positionen von Jennifer Kaufman-Shaw
| Unternehmen | Position | Beginn |
|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
| Alberta Bar Association | Corporate Officer/Principal | - |
British Columbia Bar Association
 British Columbia Bar Association Miscellaneous Commercial ServicesCommercial Services British Columbia Bar Association Operates as a law firm association to provide legal services. The company is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Jennifer Kaufman-Shaw
| Unternehmen | Position | Ende |
|---|---|---|
ImStar Therapeutics, Inc.
 ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Founder | 01.07.2014 |
Sirius Genomics, Inc.
 Sirius Genomics, Inc. Pharmaceuticals: MajorHealth Technology Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 01.05.2012 |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 01.07.2007 |
MRM Proteomics, Inc.
 MRM Proteomics, Inc. BiotechnologyHealth Technology MRM Proteomics, Inc. provides proteomics services. Its products include PeptiQuant, protein quant and quality control kits. The firm offers PeptiQuant protein quantitation, protein characterization and tissue imaging services. The company was founded in 2010 and is headquartered in Montreal, Canada. | Director/Board Member | - |
Ausbildung von Jennifer Kaufman-Shaw
| University of Alberta | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| Alberta Bar Association | |
British Columbia Bar Association
British Columbia Bar Association Miscellaneous Commercial ServicesCommercial Services British Columbia Bar Association Operates as a law firm association to provide legal services. The company is headquartered in Vancouver, Canada. | Commercial Services |
Sirius Genomics, Inc.
Sirius Genomics, Inc. Pharmaceuticals: MajorHealth Technology Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada. | Health Technology |
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Health Technology |
MRM Proteomics, Inc.
MRM Proteomics, Inc. BiotechnologyHealth Technology MRM Proteomics, Inc. provides proteomics services. Its products include PeptiQuant, protein quant and quality control kits. The firm offers PeptiQuant protein quantitation, protein characterization and tissue imaging services. The company was founded in 2010 and is headquartered in Montreal, Canada. | Health Technology |
